NCT07281833
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07281833
Title Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib Alongside Standard-of-care Endocrine Treatment in Patients With HR+/HER2- Advanced Breast Cancer and Progression on Prior Endocrine-based Treatment (CAPIcorn)
Acronym CAPIcorn
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors West German Study Group
Indications
Therapies
Age Groups: adult | senior
Covered Countries DEU | BEL

Facility Status City State Zip Country Details
Institut Jules Bordet NOT_YET_RECRUITING Anderlecht 1070 Belgium Details
CHC MontLegia NOT_YET_RECRUITING Liège 4000 Belgium Details
St. Elisabeth-Krankenhaus GmbH, Brustzentrum - Senologie NOT_YET_RECRUITING Cologne North Rhine-Westphalia 50935 Germany Details
Universitätsklinikum Essen NOT_YET_RECRUITING Essen North Rhine-Westphalia 45130 Germany Details
Brustzentrum Niederrhein, Johanniter Bethesda Krankenhaus RECRUITING Mönchengladbach North Rhine-Westphalia 41061 Germany Details
Universitätsklinikum Münster AöR Brustzentrum NOT_YET_RECRUITING Münster North Rhine-Westphalia 48149 Germany Details
Champalimaud Clinical Centre NOT_YET_RECRUITING Lisbon 1400-038 Portugal Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field